Tenecteplase versus Alteplase for the Management of Acute Ischemic Stroke in a Low-income Country–Nepal: Cost, Efficacy, and Safety
Open Access
- 9 February 2018
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 10 (2) , e2178
Abstract
Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered, mutant tissue plasminogen activator, is an alternative thrombolytic agent. The economic feasibility of stroke treatment has been a matter of huge debate and discussion thus far. The use of thrombolytics for the management of ischemic stroke has recently begun in Nepal. In low-income countries like Nepal, where the per capita income falls at just $691.7 and 25.2% of the population are under the poverty line, stroke patients cannot meet treatment expenses. Tenecteplase is easily available (for the management of acute coronary syndrome) in tertiary-level hospitals of Nepal and the price quote of tenecteplase ($450) is half the price of alteplase ($1000). In emergency cases, sometimes, the cost of alteplase can be greater than the patient can afford and they can't undergo thrombolysis even after arriving on time. However, evidence exists that supports the use of other alternatives (tenecteplase), which are also effective in the management of acute ischemic stroke. In this article, we examined current evidence for the efficacy and safety of tenecteplase when compared to alteplase. This review will make neurologists in Nepal familiar with the efficacy and safety of tenecteplase in comparison with alteplase since it is common for patients to not be able to afford the expensive alteplase, which makes guideline-based practice impossible some times.Keywords
This publication has 18 references indexed in Scilit:
- Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysisThe Lancet Neurology, 2016
- Feasibility and efficacy of thrombolysis in acute ischemic stroke: A study from National Institute of Neurological and Allied Sciences, Kathmandu, NepalJournal of Neurosciences in Rural Practice, 2016
- Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint studyThe Lancet Neurology, 2015
- A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic StrokeNew England Journal of Medicine, 2012
- Low Rates of Acute Recanalization With Intravenous Recombinant Tissue Plasminogen Activator in Ischemic StrokeStroke, 2010
- Phase IIB/III Trial of Tenecteplase in Acute Ischemic StrokeStroke, 2010
- Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarctionAmerican Heart Journal, 2003
- Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trialThe Lancet, 1999
- New Variant of Human Tissue Plasminogen Activator (TPA) With Enhanced Efficacy and Lower Incidence of Bleeding Compared With Recombinant Human TPACirculation, 1995
- A faster-acting and more potent form of tissue plasminogen activator.Proceedings of the National Academy of Sciences, 1994